Disputable charges found in 91 days of invoices. Each is listed below with its evidence.
Period findings × 365 / 91 days. An estimate, not a result.
Third-party billing during facility-responsible stays. Not savings.
Net of credits. $38.04 per facility-paid resident-day.
We reviewed 3,433 invoice lines across 3 invoice(s) from Northbridge Institutional Pharmacy (fictional), matched them to 137 residents' census records (8,638 resident-days, average daily census 94.9) and tested them against the pharmacy services agreement.
Identified overbilling is $14,111.23, or 19.0% of net facility-paid charges ($74,420.89). At this run-rate that is an estimated $56,600 a year.
Separately, $1,809.04 of drugs were billed to Part D or another third party while the facility was responsible for the resident's drugs. Correcting this raises facility cost; it reduces regulatory exposure.
$3,178.70 of facility-billed drug charges (3.9% of $81,987.39) fell on days the facility was not in a Part A or facility-responsible managed-care stay. We classified every line: $880.37 should have gone to Part D or Medicaid; $1,784.32 in Part D rejections to review; $45.99 of possible hospice responsibility; $190.28 in retroactive Medicaid credits; $6.00 in OTC pricing above contract. $9.00 appears legitimate under the agreement.
The earliest open dispute deadline under the agreement's 90-day window is October 29, 2026.
Substitution opportunities (estimate, clinical review required): $10,861.06. Not included in the totals above.
| Check | Type | Findings | Lines | Amount | ||
|---|---|---|---|---|---|---|
| 1 | Payer misbilling (Part A vs. Part D / Medicaid) | Overbilling | 9 | 21 | $902.87 | |
| 1 | Third-party billing during a facility-responsible stay (compliance exposure) | Exposure | 4 | 6 | $1,809.04 | |
| 2 | Charges after discharge, death or leave of absence | Overbilling | 10 | 20 | $2,659.24 | |
| 3 | Duplicates and missing credits | Overbilling | 14 | 59 | $5,253.74 | |
| 4 | Fees against contract | Overbilling | 8 | 320 | $1,006.25 | |
| 5 | Consolidated billing exclusions billed to the facility | Overbilling | 4 | 4 | $1,916.70 | |
| 6 | Price against contract | Overbilling | 2 | 18 | $295.84 | |
| 7 | Substitution opportunities (clinical review required) | Estimate | 4 | 57 | $10,861.06 | |
| 8 | Facility charges outside Part A | Overbilling | 10 | 43 | $2,076.59 | |
| Identified overbilling (disputable) | $14,111.23 | |||||
| Compliance exposure (not savings) | $1,809.04 | |||||
| Substitution opportunity (estimate) | $10,861.06 |
No invoice dollar is counted twice: when a line fails more than one check, the higher-priority check keeps it.
When a resident is in a covered Part A stay, the facility is responsible for their drugs out of the per-diem rate. Drugs billed to Part D (or Medicaid) on those days are improper payments. The OIG has an open Work Plan item on SNFs' financial responsibility for drugs for Part D enrollees in Part A stays, and its audit A-09-21-03008 found up to $465.1M in improper Part D payments of this kind (oig.hhs.gov).
These items do not save money. Correcting them shifts cost to the facility. We list them so the facility can fix the billing before an auditor finds it. This is not legal advice; review with compliance counsel.
| ID | Resident | Issue | Lines | Amount |
|---|---|---|---|---|
| C1-001 | R1098 | Part D billed during a Medicare Part A stay | 2 | $646.80 |
| C1-002 | R1100 | Part D billed during a Medicare Part A stay | 2 | $606.48 |
| C1-003 | R1099 | Part D billed during a Medicare Part A stay | 1 | $326.80 |
| C1-004 | R1101 | Part D billed during a Medicare Part A stay | 1 | $228.96 |
Facility-paid outside Part A: $3,178.70 across 57 drug lines, 3.9% of facility-billed drug charges ($81,987.39). $2,906.96 (91.5%) of it is flagged for review or dispute.
On these days the facility is not responsible for drugs under a Part A stay. Every line was classified in this order: hospice, Medicaid pending, OTC, Part D rejection, contract guarantee, and otherwise "should have gone to Part D / Medicaid" (reported under check 1). "Flagged" counts any check's finding on the line, after de-duplication; linked dispensing fees are in the finding detail, not in this table.
| Bucket | Lines | Billed | Share | Flagged | Reported as |
|---|---|---|---|---|---|
| Should have gone to Part D / Medicaid | 12 | $880.37 | 27.7% | $880.37 | Check 1 findings |
| Part D rejection passed through to the facility non-formulary $403.70; other reject reasons $349.27; plan limits / quantity $505.68; prior authorization $296.35; refill too soon $229.32 | 5 | $1,784.32 | 56.1% | $1,784.32 | Check 8 findings |
| Possible hospice responsibility | 3 | $45.99 | 1.4% | $45.99 | Check 8 findings |
| Medicaid pending (fronted by the facility) covered by a retroactive approval $299.18; still pending (watch list) $146.04 | 28 | $445.22 | 14.0% | $190.28 | Check 8 findings |
| OTC / house stock above contract OTC terms $13.80 | 3 | $13.80 | 0.4% | $6.00 | Check 8 findings |
| Legitimate under the agreement OTC priced within contract terms $9.00 | 6 | $9.00 | 0.3% | $0.00 | No finding |
| Total outside Part A | 57 | $3,178.70 | 100% | $2,906.96 |
Part D rejections are flagged as avoidable rejections for review, not as amounts the pharmacy owes. Hospice items need the hospice and the consultant pharmacist to confirm relatedness: we do not receive diagnoses. Charges still in a Medicaid-pending period are listed under credits to watch, not as findings.
Each finding lists the invoice lines, the census record for the service date, the contract clause and a recommended action. Flagged amounts are what the facility can request.
2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.
Census: R1003 in house, payer Medicaid, from 04/14/2026. Last census event: admit on 04/14/2026 (payer Medicaid).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-21 | 08/01/2026 | R1003 | Memantine 10 mg TAB | 99999001001 | 62 | Facility | $86.49 | $86.49 |
| INV-202608-22 | 08/01/2026 | R1003 | Seroquel 50 mg TAB | 99999004301 | 31 | Facility | $479.14 | $479.14 |
| INV-202608-23 | 08/01/2026 | R1003 | Dispensing Fee | 99999001001 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-24 | 08/01/2026 | R1003 | Dispensing Fee | 99999004301 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.
Census: R1007 in house, payer Medicaid, from 10/17/2025. Last census event: admit on 10/17/2025 (payer Medicaid).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-48 | 08/01/2026 | R1007 | Memantine 10 mg TAB | 99999001001 | 62 | Facility | $86.49 | $86.49 |
| INV-202608-51 | 08/01/2026 | R1007 | Dispensing Fee | 99999001001 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.
Census: R1008 in house, payer Medicaid, from 04/01/2025. Last census event: admit on 04/01/2025 (payer Medicaid).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-54 | 08/01/2026 | R1008 | Pantoprazole 40 mg TAB EC | 99999000601 | 31 | Facility | $64.48 | $64.48 |
| INV-202608-59 | 08/01/2026 | R1008 | Dispensing Fee | 99999000601 | 1 | Facility | $2.50 | $2.50 |
2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.
Census: R1006 in house, payer Medicaid, from 04/18/2026. Last census event: admit on 04/18/2026 (payer Medicaid).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-41 | 08/01/2026 | R1006 | Donepezil 10 mg TAB | 99999000901 | 31 | Facility | $39.06 | $39.06 |
| INV-202608-44 | 08/01/2026 | R1006 | Carvedilol 6.25 mg TAB | 99999001801 | 62 | Facility | $20.93 | $20.93 |
| INV-202608-45 | 08/01/2026 | R1006 | Dispensing Fee | 99999000901 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-46 | 08/01/2026 | R1006 | Dispensing Fee | 99999001801 | 1 | Facility | $2.50 | $2.50 |
2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.
Census: R1004 in house, payer Medicaid, from 07/08/2023. Last census event: admit on 07/08/2023 (payer Medicaid).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-27 | 08/01/2026 | R1004 | Quetiapine 25 mg TAB | 99999001701 | 62 | Facility | $33.48 | $33.48 |
| INV-202608-28 | 08/01/2026 | R1004 | Carvedilol 6.25 mg TAB | 99999001801 | 62 | Facility | $20.93 | $20.93 |
| INV-202608-31 | 08/01/2026 | R1004 | Dispensing Fee | 99999001701 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-32 | 08/01/2026 | R1004 | Dispensing Fee | 99999001801 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/01/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.
Census: R1009 in house, payer Medicaid, from 08/12/2025. Last census event: admit on 08/12/2025 (payer Medicaid).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-64 | 08/01/2026 | R1009 | Mirtazapine 15 mg TAB | 99999002401 | 31 | Facility | $15.35 | $15.35 |
| INV-202608-65 | 08/01/2026 | R1009 | Dispensing Fee | 99999002401 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) dispensed 08/09/2026 were billed to the facility. On those dates the census payer was Medicaid, and the contract assigns drug cost for Medicaid days to Medicaid / Part D plan.
Census: R1081 in house, payer Medicaid, from 08/04/2026. Last census event: payer change on 08/04/2026 (payer Medicaid).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Medicaid / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-807 | 08/09/2026 | R1081 | Cephalexin 500 mg CAP | 99999006001 | 28 | Facility | $11.34 | $11.34 |
1 drug line(s) dispensed 08/13/2026 were billed to the facility. On those dates the census payer was Private, and the contract assigns drug cost for Private days to Resident / Part D plan.
Census: R1083 in house, payer Private, from 08/06/2026. Last census event: payer change on 08/06/2026 (payer Private).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Resident / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-885 | 08/13/2026 | R1083 | Cephalexin 500 mg CAP | 99999006001 | 28 | Facility | $11.34 | $11.34 |
1 drug line(s) dispensed 07/27/2026 were billed to the facility. On those dates the census payer was Private, and the contract assigns drug cost for Private days to Resident / Part D plan.
Census: R1087 in house, payer Private, from 07/20/2026. Last census event: payer change on 07/20/2026 (payer Private).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Request a credit for these lines and ask the pharmacy to rebill Resident / Part D plan. Ask the pharmacy to confirm its payer feed from the census.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-994 | 07/27/2026 | R1087 | Cephalexin 500 mg CAP | 99999006001 | 28 | Facility | $11.34 | $11.34 |
2 drug line(s) dispensed 07/11/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.
Census: R1098 in house, payer MedicareA, 07/11/2026–08/18/2026. Last census event: admit on 07/11/2026 (payer MedicareA).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-808 | 07/11/2026 | R1098 | Eliquis 5 mg TAB | 99999004001 | 42 | PartD | $329.28 | $329.28 |
| INV-202607-810 | 07/11/2026 | R1098 | Januvia 100 mg TAB | 99999004701 | 21 | PartD | $317.52 | $317.52 |
2 drug line(s) dispensed 07/13/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.
Census: R1100 in house, payer MedicareA, 07/13/2026–07/28/2026. Last census event: admit on 07/13/2026 (payer MedicareA).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-854 | 07/13/2026 | R1100 | Jardiance 10 mg TAB | 99999004101 | 19 | PartD | $326.80 | $326.80 |
| INV-202607-855 | 07/13/2026 | R1100 | Seroquel 50 mg TAB | 99999004301 | 19 | PartD | $279.68 | $279.68 |
1 drug line(s) dispensed 07/13/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.
Census: R1099 in house, payer MedicareA, 07/13/2026–08/10/2026. Last census event: admit on 07/13/2026 (payer MedicareA).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-834 | 07/13/2026 | R1099 | Jardiance 10 mg TAB | 99999004101 | 19 | PartD | $326.80 | $326.80 |
1 drug line(s) dispensed 07/23/2026 were billed to Part D. On those dates the resident was in a Medicare Part A stay, when drug cost is the facility's responsibility under the stay's payment. This is the pattern the OIG examined in audit A-09-21-03008.
Census: R1101 in house, payer MedicareA, 07/23/2026–08/06/2026. Last census event: admit on 07/23/2026 (payer MedicareA).
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Ask the pharmacy to reverse the third-party claims and rebill under the facility account. Expect the facility's drug cost to rise by this amount. Review with compliance counsel; this is not legal advice.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-924 | 07/23/2026 | R1101 | Namenda 10 mg TAB | 99999004401 | 18 | PartD | $228.96 | $228.96 |
2 facility-billed line(s) (1 fee line(s)) dated 07/06/2026, while transferred to hospital. The resident was not in the building on these service dates.
Census: R1086 in hospital (transferred out) 07/06/2026–07/09/2026 (last payer MedicareA). Last census event: hospital transfer on 07/05/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-708 | 07/06/2026 | R1086 | Namenda 10 mg TAB | 99999004401 | 28 | Facility | $373.97 | $373.97 |
| INV-202607-709 | 07/06/2026 | R1086 | Dispensing Fee | 99999004401 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 07/31/2026, after discharge. The resident was not in the building on these service dates.
Census: R1086 discharged from 07/28/2026 (last payer MedicareA). Last census event: discharge on 07/27/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-1032 | 07/31/2026 | R1086 | Namenda 10 mg TAB | 99999004401 | 28 | Facility | $373.97 | $373.97 |
| INV-202607-1033 | 07/31/2026 | R1086 | Dispensing Fee | 99999004401 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 08/30/2026, after death. The resident was not in the building on these service dates.
Census: R1102 deceased from 08/28/2026 (last payer MedicareA). Last census event: death on 08/27/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-1185 | 08/30/2026 | R1102 | Namenda 10 mg TAB | 99999004401 | 28 | Facility | $373.97 | $373.97 |
| INV-202608-1186 | 08/30/2026 | R1102 | Dispensing Fee | 99999004401 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 07/12/2026, after discharge. The resident was not in the building on these service dates.
Census: R1088 discharged from 07/10/2026 (last payer MedicareA). Last census event: discharge on 07/09/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-821 | 07/12/2026 | R1088 | Entresto 49-51 mg TAB | 99999004801 | 28 | Facility | $263.42 | $263.42 |
| INV-202607-822 | 07/12/2026 | R1088 | Dispensing Fee | 99999004801 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 07/22/2026, while transferred to hospital. The resident was not in the building on these service dates.
Census: R1089 in hospital (transferred out) 07/22/2026–07/24/2026 (last payer MedicareA). Last census event: hospital transfer on 07/21/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-904 | 07/22/2026 | R1089 | Entresto 49-51 mg TAB | 99999004801 | 28 | Facility | $263.42 | $263.42 |
| INV-202607-905 | 07/22/2026 | R1089 | Dispensing Fee | 99999004801 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 07/10/2026, after discharge. The resident was not in the building on these service dates.
Census: R1085 discharged from 07/06/2026 (last payer MedicareA). Last census event: discharge on 07/05/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-778 | 07/10/2026 | R1085 | Jardiance 10 mg TAB | 99999004101 | 14 | Facility | $252.84 | $252.84 |
| INV-202607-779 | 07/10/2026 | R1085 | Dispensing Fee | 99999004101 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 08/13/2026, after death. The resident was not in the building on these service dates.
Census: R1099 deceased from 08/11/2026 (last payer MedicareA). Last census event: death on 08/10/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-886 | 08/13/2026 | R1099 | Jardiance 10 mg TAB | 99999004101 | 14 | Facility | $252.84 | $252.84 |
| INV-202608-887 | 08/13/2026 | R1099 | Dispensing Fee | 99999004101 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 07/04/2026, after discharge. The resident was not in the building on these service dates.
Census: R1084 discharged from 07/02/2026 (last payer MedicareA). Last census event: discharge on 07/01/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-703 | 07/04/2026 | R1084 | Eliquis 5 mg TAB | 99999004001 | 28 | Facility | $230.50 | $230.50 |
| INV-202607-704 | 07/04/2026 | R1084 | Dispensing Fee | 99999004001 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 08/01/2026, during leave of absence. The resident was not in the building on these service dates.
Census: R1103 on leave of absence 08/01/2026–08/01/2026 (last payer MedicareA). Last census event: loa start on 07/31/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-662 | 08/01/2026 | R1103 | Linzess 145 mcg CAP | 99999004901 | 14 | Facility | $209.33 | $209.33 |
| INV-202608-663 | 08/01/2026 | R1103 | Dispensing Fee | 99999004901 | 1 | Facility | $2.50 | $2.50 |
2 facility-billed line(s) (1 fee line(s)) dated 08/14/2026, during leave of absence. The resident was not in the building on these service dates.
Census: R1112 on leave of absence 08/14/2026–08/14/2026 (last payer MedicareA). Last census event: loa start on 08/13/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Request full credit. If the pharmacy states the medication was delivered and used, ask for the delivery manifest signed by facility staff.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-906 | 08/14/2026 | R1112 | Synthroid 75 mcg TAB | 99999004501 | 14 | Facility | $39.98 | $39.98 |
| INV-202608-907 | 08/14/2026 | R1112 | Dispensing Fee | 99999004501 | 1 | Facility | $2.50 | $2.50 |
Resident discharge on 07/06/2026. 7 facility-paid fill(s) had unused, returnable supply (25, 25, 25, 25, 25, 25, 25 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.
Census: R1092 discharged from 07/07/2026 (last payer MedicareA). Last census event: discharge on 07/06/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-641 | 07/01/2026 | R1092 | Senna 8.6 mg TAB | 99999001301 | 62 | Facility | $2.79 | $2.25 |
| INV-202607-642 | 07/01/2026 | R1092 | Acetaminophen 500 mg TAB | 99999001501 | 93 | Facility | $2.51 | $2.02 |
| INV-202607-643 | 07/01/2026 | R1092 | Tamsulosin 0.4 mg CAP | 99999001601 | 31 | Facility | $22.32 | $18.00 |
| INV-202607-645 | 07/01/2026 | R1092 | Escitalopram 10 mg TAB | 99999002301 | 31 | Facility | $20.93 | $16.88 |
| INV-202607-646 | 07/01/2026 | R1092 | Mirtazapine 15 mg TAB | 99999002401 | 31 | Facility | $15.35 | $12.38 |
| INV-202607-647 | 07/01/2026 | R1092 | Eliquis 5 mg TAB | 99999004001 | 62 | Facility | $510.38 | $411.60 |
| INV-202607-648 | 07/01/2026 | R1092 | Namenda 10 mg TAB | 99999004401 | 62 | Facility | $828.07 | $667.80 |
Resident discharge on 07/05/2026. 8 facility-paid fill(s) had unused, returnable supply (26, 26, 26, 26, 26, 26, 26, 26 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.
Census: R1085 discharged from 07/06/2026 (last payer MedicareA). Last census event: discharge on 07/05/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-545 | 07/01/2026 | R1085 | Donepezil 10 mg TAB | 99999000901 | 31 | Facility | $39.06 | $32.76 |
| INV-202607-546 | 07/01/2026 | R1085 | Memantine 10 mg TAB | 99999001001 | 62 | Facility | $86.49 | $72.54 |
| INV-202607-547 | 07/01/2026 | R1085 | Metformin 500 mg TAB | 99999001101 | 62 | Facility | $9.77 | $8.19 |
| INV-202607-548 | 07/01/2026 | R1085 | Acetaminophen 500 mg TAB | 99999001501 | 93 | Facility | $2.51 | $2.11 |
| INV-202607-549 | 07/01/2026 | R1085 | Vitamin D3 1000 unit TAB | 99999001901 | 31 | Facility | $0.70 | $0.59 |
| INV-202607-552 | 07/01/2026 | R1085 | Escitalopram 10 mg TAB | 99999002301 | 31 | Facility | $20.93 | $17.55 |
| INV-202607-553 | 07/01/2026 | R1085 | Jardiance 10 mg TAB | 99999004101 | 31 | Facility | $559.86 | $469.56 |
| INV-202607-554 | 07/01/2026 | R1085 | Lipitor 40 mg TAB | 99999004201 | 31 | Facility | $369.77 | $310.13 |
Resident discharge on 08/13/2026. 7 facility-paid fill(s) had unused, returnable supply (18, 18, 18, 18, 18, 18, 18 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.
Census: R1089 discharged from 08/14/2026 (last payer MedicareA). Last census event: discharge on 08/13/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-508 | 08/01/2026 | R1089 | Amlodipine 5 mg TAB | 99999000101 | 31 | Facility | $11.86 | $6.89 |
| INV-202608-509 | 08/01/2026 | R1089 | Furosemide 40 mg TAB | 99999000501 | 31 | Facility | $5.58 | $3.24 |
| INV-202608-510 | 08/01/2026 | R1089 | Levothyroxine 50 mcg TAB | 99999000701 | 31 | Facility | $12.56 | $7.29 |
| INV-202608-511 | 08/01/2026 | R1089 | Sertraline 50 mg TAB | 99999000801 | 31 | Facility | $19.53 | $11.34 |
| INV-202608-514 | 08/01/2026 | R1089 | Jardiance 10 mg TAB | 99999004101 | 31 | Facility | $559.86 | $325.08 |
| INV-202608-515 | 08/01/2026 | R1089 | Lipitor 40 mg TAB | 99999004201 | 31 | Facility | $369.77 | $214.71 |
| INV-202608-516 | 08/01/2026 | R1089 | Entresto 49-51 mg TAB | 99999004801 | 62 | Facility | $583.30 | $338.69 |
Resident discharge on 08/16/2026. 10 facility-paid fill(s) had unused, returnable supply (15, 15, 15, 15, 15, 15, 15, 15, 15, 15 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.
Census: R1104 discharged from 08/17/2026 (last payer MedicareA). Last census event: discharge on 08/16/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-1012 | 07/30/2026 | R1104 | Amlodipine 5 mg TAB | 99999000101 | 33 | Facility | $12.62 | $5.74 |
| INV-202607-1013 | 07/30/2026 | R1104 | Pantoprazole 40 mg TAB EC | 99999000601 | 33 | Facility | $47.52 | $21.60 |
| INV-202607-1014 | 07/30/2026 | R1104 | Memantine 10 mg TAB | 99999001001 | 66 | Facility | $92.07 | $41.85 |
| INV-202607-1015 | 07/30/2026 | R1104 | Gabapentin 300 mg CAP | 99999001201 | 99 | Facility | $31.19 | $14.18 |
| INV-202607-1016 | 07/30/2026 | R1104 | Acetaminophen 500 mg TAB | 99999001501 | 99 | Facility | $2.67 | $1.21 |
| INV-202607-1017 | 07/30/2026 | R1104 | Quetiapine 25 mg TAB | 99999001701 | 66 | Facility | $35.64 | $16.20 |
| INV-202607-1018 | 07/30/2026 | R1104 | Carvedilol 6.25 mg TAB | 99999001801 | 66 | Facility | $22.28 | $10.13 |
| INV-202607-1019 | 07/30/2026 | R1104 | Escitalopram 10 mg TAB | 99999002301 | 33 | Facility | $22.28 | $10.13 |
| INV-202607-1020 | 07/30/2026 | R1104 | Namenda 10 mg TAB | 99999004401 | 66 | Facility | $881.50 | $400.68 |
| INV-202607-1021 | 07/30/2026 | R1104 | Entresto 49-51 mg TAB | 99999004801 | 66 | Facility | $620.93 | $282.24 |
Resident death on 08/10/2026. 9 facility-paid fill(s) had unused, returnable supply (21, 21, 21, 21, 21, 21, 21, 21, 21 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show no credit. Controlled substances are excluded.
Census: R1099 deceased from 08/11/2026 (last payer MedicareA). Last census event: death on 08/10/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-602 | 08/01/2026 | R1099 | Amlodipine 5 mg TAB | 99999000101 | 31 | Facility | $11.86 | $8.03 |
| INV-202608-603 | 08/01/2026 | R1099 | Furosemide 40 mg TAB | 99999000501 | 31 | Facility | $5.58 | $3.78 |
| INV-202608-604 | 08/01/2026 | R1099 | Donepezil 10 mg TAB | 99999000901 | 31 | Facility | $39.06 | $26.46 |
| INV-202608-605 | 08/01/2026 | R1099 | Metformin 500 mg TAB | 99999001101 | 62 | Facility | $9.77 | $6.62 |
| INV-202608-606 | 08/01/2026 | R1099 | Senna 8.6 mg TAB | 99999001301 | 62 | Facility | $2.79 | $1.89 |
| INV-202608-607 | 08/01/2026 | R1099 | Docusate 100 mg CAP | 99999001401 | 62 | Facility | $2.23 | $1.51 |
| INV-202608-608 | 08/01/2026 | R1099 | Acetaminophen 500 mg TAB | 99999001501 | 93 | Facility | $2.51 | $1.70 |
| INV-202608-610 | 08/01/2026 | R1099 | Jardiance 10 mg TAB | 99999004101 | 31 | Facility | $559.86 | $379.26 |
| INV-202608-611 | 08/01/2026 | R1099 | Seroquel 50 mg TAB | 99999004301 | 31 | Facility | $479.14 | $324.58 |
Resident discharge on 07/09/2026. 11 facility-paid fill(s) had unused, returnable supply (22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22 days). Expected credit at 100% of the unused share; invoices through 09/30/2026 show a partial credit. Controlled substances are excluded.
Census: R1088 discharged from 07/10/2026 (last payer MedicareA). Last census event: discharge on 07/09/2026.
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Confirm the medication was returned to the pharmacy (return log or destruction record), then request the credit.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-599 | 07/01/2026 | R1088 | Furosemide 40 mg TAB | 99999000501 | 31 | Facility | $5.58 | $1.98 |
| INV-202607-600 | 07/01/2026 | R1088 | Pantoprazole 40 mg TAB EC | 99999000601 | 31 | Facility | $44.64 | $15.84 |
| INV-202607-601 | 07/01/2026 | R1088 | Metformin 500 mg TAB | 99999001101 | 62 | Facility | $9.77 | $3.46 |
| INV-202607-602 | 07/01/2026 | R1088 | Gabapentin 300 mg CAP | 99999001201 | 93 | Facility | $29.30 | $10.39 |
| INV-202607-603 | 07/01/2026 | R1088 | Acetaminophen 500 mg TAB | 99999001501 | 93 | Facility | $2.51 | $0.89 |
| INV-202607-604 | 07/01/2026 | R1088 | Carvedilol 6.25 mg TAB | 99999001801 | 62 | Facility | $20.93 | $7.42 |
| INV-202607-607 | 07/01/2026 | R1088 | Mirtazapine 15 mg TAB | 99999002401 | 31 | Facility | $15.35 | $5.44 |
| INV-202607-608 | 07/01/2026 | R1088 | Seroquel 50 mg TAB | 99999004301 | 31 | Facility | $479.14 | $170.01 |
| INV-202607-609 | 07/01/2026 | R1088 | Xarelto 20 mg TAB | 99999004601 | 31 | Facility | $507.78 | $180.18 |
| INV-202607-610 | 07/01/2026 | R1088 | Entresto 49-51 mg TAB | 99999004801 | 62 | Facility | $583.30 | $206.97 |
Memantine 10 mg TAB was dispensed 08/01/2026 for 31 days (through 08/31/2026) and dispensed again 08/12/2026. 20 days of supply overlap and no credit for the first fill appears. Flagged amount is the overlapping share of the second fill.
Census: R1063 in house, payer ManagedCare, from 11/13/2024. Last census event: admit on 11/13/2024 (payer ManagedCare).
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Check the order history for a dose change. If none, request credit for the overlapping supply or return of the first fill.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-866 | 08/12/2026 | R1063 | Memantine 10 mg TAB | 99999001001 | 40 | Facility | $55.80 | $55.80 |
| INV-202608-332 | 08/01/2026 | R1063 | Memantine 10 mg TAB | 99999001001 | 62 | Facility | $86.49 | $0.00 |
Gabapentin 300 mg CAP (NDC 99999001201), qty 93, $29.30 dispensed 07/01/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-569) is treated as valid; 1 repeat charge(s) are flagged.
Census: R1086 in house, payer MedicareA, 06/11/2026–07/05/2026. Last census event: admit on 06/11/2026 (payer MedicareA).
§9.2 (Invoice Disputes): disputes within 90 days of invoice date
Request credit for each repeat charge.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-2 | 07/01/2026 | R1086 | Gabapentin 300 mg CAP | 99999001201 | 93 | Facility | $29.30 | $29.30 |
| INV-202607-569 | 07/01/2026 | R1086 | Gabapentin 300 mg CAP | 99999001201 | 93 | Facility | $29.30 | $0.00 |
Escitalopram 10 mg TAB (NDC 99999002301), qty 29, $19.58 dispensed 09/02/2026 was billed 2 times (invoices INV-202609). The first charge (line INV-202609-814) is treated as valid; 1 repeat charge(s) are flagged.
Census: R1123 in house, payer MedicareA, 09/02/2026–09/30/2026. Last census event: admit on 09/02/2026 (payer MedicareA).
§9.2 (Invoice Disputes): disputes within 90 days of invoice date
Request credit for each repeat charge.
12/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202609-815 | 09/02/2026 | R1123 | Escitalopram 10 mg TAB | 99999002301 | 29 | Facility | $19.58 | $19.58 |
| INV-202609-814 | 09/02/2026 | R1123 | Escitalopram 10 mg TAB | 99999002301 | 29 | Facility | $19.58 | $0.00 |
Mirtazapine 15 mg TAB (NDC 99999002401), qty 31, $15.35 dispensed 07/01/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-372) is treated as valid; 1 repeat charge(s) are flagged.
Census: R1064 in house, payer ManagedCare, from 04/17/2025. Last census event: admit on 04/17/2025 (payer ManagedCare).
§9.2 (Invoice Disputes): disputes within 90 days of invoice date
Request credit for each repeat charge.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-1 | 07/01/2026 | R1064 | Mirtazapine 15 mg TAB | 99999002401 | 31 | Facility | $15.35 | $15.35 |
| INV-202607-372 | 07/01/2026 | R1064 | Mirtazapine 15 mg TAB | 99999002401 | 31 | Facility | $15.35 | $0.00 |
Escitalopram 10 mg TAB (NDC 99999002301), qty 19, $12.83 dispensed 07/13/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-852) is treated as valid; 1 repeat charge(s) are flagged.
Census: R1100 in house, payer MedicareA, 07/13/2026–07/28/2026. Last census event: admit on 07/13/2026 (payer MedicareA).
§9.2 (Invoice Disputes): disputes within 90 days of invoice date
Request credit for each repeat charge.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-5 | 07/13/2026 | R1100 | Escitalopram 10 mg TAB | 99999002301 | 19 | Facility | $12.83 | $12.83 |
| INV-202607-852 | 07/13/2026 | R1100 | Escitalopram 10 mg TAB | 99999002301 | 19 | Facility | $12.83 | $0.00 |
Furosemide 40 mg TAB (NDC 99999000501), qty 31, $5.58 dispensed 07/01/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-599) is treated as valid; 1 repeat charge(s) are flagged.
Census: R1088 in house, payer MedicareA, 06/26/2026–07/09/2026. Last census event: admit on 06/26/2026 (payer MedicareA).
§9.2 (Invoice Disputes): disputes within 90 days of invoice date
Request credit for each repeat charge.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-3 | 07/01/2026 | R1088 | Furosemide 40 mg TAB | 99999000501 | 31 | Facility | $5.58 | $5.58 |
| INV-202607-599 | 07/01/2026 | R1088 | Furosemide 40 mg TAB | 99999000501 | 31 | Facility | $5.58 | $0.00 |
Senna 8.6 mg TAB (NDC 99999001301), qty 38, $1.71 dispensed 07/13/2026 was billed 2 times (invoices INV-202607, INV-202608). The first charge (line INV-202607-830) is treated as valid; 1 repeat charge(s) are flagged.
Census: R1099 in house, payer MedicareA, 07/13/2026–08/10/2026. Last census event: admit on 07/13/2026 (payer MedicareA).
§9.2 (Invoice Disputes): disputes within 90 days of invoice date
Request credit for each repeat charge.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-4 | 07/13/2026 | R1099 | Senna 8.6 mg TAB | 99999001301 | 38 | Facility | $1.71 | $1.71 |
| INV-202607-830 | 07/13/2026 | R1099 | Senna 8.6 mg TAB | 99999001301 | 38 | Facility | $1.71 | $0.00 |
Acetaminophen 500 mg TAB was dispensed 08/01/2026 for 31 days (through 08/31/2026) and dispensed again 08/12/2026. 20 days of supply overlap and no credit for the first fill appears. Flagged amount is the overlapping share of the second fill.
Census: R1028 in house, payer ManagedCare, from 09/20/2024. Last census event: admit on 09/20/2024 (payer ManagedCare).
§7.3 (Returns and Credits): full credit for unused unit-dose medication on discharge, death or discontinuation
Check the order history for a dose change. If none, request credit for the overlapping supply or return of the first fill.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-865 | 08/12/2026 | R1028 | Acetaminophen 500 mg TAB | 99999001501 | 60 | Facility | $1.62 | $1.62 |
| INV-202608-157 | 08/01/2026 | R1028 | Acetaminophen 500 mg TAB | 99999001501 | 93 | Facility | $2.51 | $0.00 |
301 dispensing fee line(s), 301 unit(s), in 2026-09. Charged $3.75 per unit against a contract rate of $2.50 per rx.
Exhibit B §2.1 (Dispensing Fee)
Request credit for the amount above contract.
12/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202609-143 | 09/01/2026 | R1028 | Dispensing Fee | 99999001501 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-144 | 09/01/2026 | R1028 | Dispensing Fee | 99999001601 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-145 | 09/01/2026 | R1028 | Dispensing Fee | 99999001801 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-146 | 09/01/2026 | R1028 | Dispensing Fee | 99999002001 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-193 | 09/01/2026 | R1038 | Dispensing Fee | 99999000101 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-194 | 09/01/2026 | R1038 | Dispensing Fee | 99999000201 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-195 | 09/01/2026 | R1038 | Dispensing Fee | 99999000301 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-196 | 09/01/2026 | R1038 | Dispensing Fee | 99999000601 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-197 | 09/01/2026 | R1038 | Dispensing Fee | 99999001101 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-198 | 09/01/2026 | R1038 | Dispensing Fee | 99999001601 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-199 | 09/01/2026 | R1038 | Dispensing Fee | 99999002301 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-231 | 09/01/2026 | R1045 | Dispensing Fee | 99999000301 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-232 | 09/01/2026 | R1045 | Dispensing Fee | 99999000801 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-233 | 09/01/2026 | R1045 | Dispensing Fee | 99999001101 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-234 | 09/01/2026 | R1045 | Dispensing Fee | 99999002301 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-235 | 09/01/2026 | R1045 | Dispensing Fee | 99999004201 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-284 | 09/01/2026 | R1055 | Dispensing Fee | 99999001401 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-285 | 09/01/2026 | R1055 | Dispensing Fee | 99999001501 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-286 | 09/01/2026 | R1055 | Dispensing Fee | 99999001901 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-287 | 09/01/2026 | R1055 | Dispensing Fee | 99999002201 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-288 | 09/01/2026 | R1055 | Dispensing Fee | 99999004801 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-333 | 09/01/2026 | R1063 | Dispensing Fee | 99999001001 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-334 | 09/01/2026 | R1063 | Dispensing Fee | 99999001201 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-335 | 09/01/2026 | R1063 | Dispensing Fee | 99999001701 | 1 | Facility | $3.75 | $1.25 |
| INV-202609-336 | 09/01/2026 | R1063 | Dispensing Fee | 99999002301 | 1 | Facility | $3.75 | $1.25 |
276 more line(s) in finding_lines.csv.
1 ekit fee line(s), 1 unit(s), in 2026-08. The contract allows 1 per month.
Exhibit B §2.4 (Emergency Kit)
Request credit for the amount above contract.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-908 | 08/15/2026 | E-Kit Monthly Fee | 1 | Facility | $150.00 | $150.00 |
7 iv admin fee line(s), 7 unit(s), in 2026-07. Charged $95.00 per unit against a contract rate of $75.00 per day.
Exhibit C §1 (Infusion Services)
Request credit for the amount above contract.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-702 | 07/03/2026 | R1095 | IV Administration Per Diem | 1 | Facility | $95.00 | $20.00 | |
| INV-202607-705 | 07/04/2026 | R1095 | IV Administration Per Diem | 1 | Facility | $95.00 | $20.00 | |
| INV-202607-706 | 07/05/2026 | R1095 | IV Administration Per Diem | 1 | Facility | $95.00 | $20.00 | |
| INV-202607-710 | 07/06/2026 | R1095 | IV Administration Per Diem | 1 | Facility | $95.00 | $20.00 | |
| INV-202607-736 | 07/07/2026 | R1095 | IV Administration Per Diem | 1 | Facility | $95.00 | $20.00 | |
| INV-202607-738 | 07/08/2026 | R1095 | IV Administration Per Diem | 1 | Facility | $95.00 | $20.00 | |
| INV-202607-775 | 07/09/2026 | R1095 | IV Administration Per Diem | 1 | Facility | $95.00 | $20.00 |
3 stat delivery fee line(s), 3 unit(s), in 2026-08. The contract allows 4 per month.
Exhibit B §2.3 (STAT Delivery)
Request credit for the amount above contract.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-1045 | 08/21/2026 | STAT Delivery | 1 | Facility | $35.00 | $35.00 | ||
| INV-202608-1046 | 08/22/2026 | STAT Delivery | 1 | Facility | $35.00 | $35.00 | ||
| INV-202608-1103 | 08/23/2026 | STAT Delivery | 1 | Facility | $35.00 | $35.00 |
5 delivery fee line(s), 5 unit(s), in 2026-07. Charged $20.00 per unit against a contract rate of $0.00 per delivery.
Exhibit B §2.2 (Delivery) (routine deliveries included)
Request credit for the amount above contract.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-700 | 07/03/2026 | Routine Delivery | 1 | Facility | $20.00 | $20.00 | ||
| INV-202607-737 | 07/08/2026 | Routine Delivery | 1 | Facility | $20.00 | $20.00 | ||
| INV-202607-824 | 07/13/2026 | Routine Delivery | 1 | Facility | $20.00 | $20.00 | ||
| INV-202607-901 | 07/18/2026 | Routine Delivery | 1 | Facility | $20.00 | $20.00 | ||
| INV-202607-906 | 07/23/2026 | Routine Delivery | 1 | Facility | $20.00 | $20.00 |
1 pkg fee line(s), 1 unit(s), in 2026-07. The agreement lists no such fee and does not permit unlisted fees.
Exhibit B §2 (Fees): no fees other than those listed
Request credit for the amount above contract.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-877 | 07/15/2026 | Packaging Fee | 1 | Facility | $45.00 | $45.00 |
1 pkg fee line(s), 1 unit(s), in 2026-08. The agreement lists no such fee and does not permit unlisted fees.
Exhibit B §2 (Fees): no fees other than those listed
Request credit for the amount above contract.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-909 | 08/15/2026 | Packaging Fee | 1 | Facility | $45.00 | $45.00 |
1 pkg fee line(s), 1 unit(s), in 2026-09. The agreement lists no such fee and does not permit unlisted fees.
Exhibit B §2 (Fees): no fees other than those listed
Request credit for the amount above contract.
12/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202609-979 | 09/15/2026 | Packaging Fee | 1 | Facility | $45.00 | $45.00 |
Leuprolide Acetate 22.5 mg DEPOT KIT (Chemotherapy; HCPCS J9217 / J9218) dispensed 07/27/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Chemotherapy HCPCS code on the CB exclusion list. Confirm the billed code and indication. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.
Census: R1102 in house, payer MedicareA, 07/24/2026–08/27/2026. Last census event: admit on 07/24/2026 (payer MedicareA).
§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing
Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-995 | 07/27/2026 | R1102 | Leuprolide Acetate 22.5 mg DEPOT KIT | 99999006301 | 1 | Facility | $1,596.00 | $1,596.00 |
Epoetin Alfa 10,000 unit/mL VIAL (ESRD-related drug (EPO); HCPCS J0885 / Q4081 / Q5106) dispensed 07/10/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Applies to ESRD-related use (resident receiving dialysis). Confirm diagnosis. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.
Census: R1097 in house, payer MedicareA, 07/08/2026–08/16/2026. Last census event: admit on 07/08/2026 (payer MedicareA).
§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing
Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-797 | 07/10/2026 | R1097 | Epoetin Alfa 10,000 unit/mL VIAL | 99999006201 | 1 | Facility | $117.60 | $117.60 |
Epoetin Alfa 10,000 unit/mL VIAL (ESRD-related drug (EPO); HCPCS J0885 / Q4081 / Q5106) dispensed 07/14/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Applies to ESRD-related use (resident receiving dialysis). Confirm diagnosis. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.
Census: R1097 in house, payer MedicareA, 07/08/2026–08/16/2026. Last census event: admit on 07/08/2026 (payer MedicareA).
§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing
Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-876 | 07/14/2026 | R1097 | Epoetin Alfa 10,000 unit/mL VIAL | 99999006201 | 1 | Facility | $117.60 | $117.60 |
Doxorubicin 50 mg VIAL (Chemotherapy; HCPCS J9000–J9999 range (verify)) dispensed 08/03/2026 during a Part A stay was billed to the facility. Drugs excluded from SNF consolidated billing are billed to Part B, not paid out of the Part A rate. Chemotherapy HCPCS code on the CB exclusion list. Confirm the billed code. Illustrative subset of the CMS SNF Consolidated Billing exclusion list (chemotherapy, ESRD-related drugs). Verify every match against the current CMS annual HCPCS exclusion file.
Census: R1104 in house, payer MedicareA, 07/30/2026–08/16/2026. Last census event: admit on 07/30/2026 (payer MedicareA).
§5.4 (Consolidated Billing): pharmacy bills Part B directly for items excluded from SNF consolidated billing
Confirm the code and indication with the clinical pharmacist, then ask the pharmacy to credit the facility and bill Part B.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-748 | 08/03/2026 | R1104 | Doxorubicin 50 mg VIAL | 99999006401 | 2 | Facility | $85.50 | $85.50 |
17 line(s) of Pantoprazole 40 mg TAB EC (NDC 99999000601) billed at $2.08 per unit. Contract price: AWP $3.2000 less 55% (generic) = $1.4400 per unit. AWP is as printed on the pharmacy invoice.
Exhibit B §1 (Drug Pricing): brand AWP less 16%; generic AWP less 55%
Request credit for the difference and ask the pharmacy to correct its price file.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-453 | 08/01/2026 | R1081 | Pantoprazole 40 mg TAB EC | 99999000601 | 31 | Facility | $64.48 | $19.84 |
| INV-202608-579 | 08/01/2026 | R1098 | Pantoprazole 40 mg TAB EC | 99999000601 | 31 | Facility | $64.48 | $19.84 |
| INV-202608-622 | 08/01/2026 | R1101 | Pantoprazole 40 mg TAB EC | 99999000601 | 31 | Facility | $64.48 | $19.84 |
| INV-202608-642 | 08/01/2026 | R1102 | Pantoprazole 40 mg TAB EC | 99999000601 | 31 | Facility | $64.48 | $19.84 |
| INV-202608-665 | 08/01/2026 | R1106 | Pantoprazole 40 mg TAB EC | 99999000601 | 31 | Facility | $64.48 | $19.84 |
| INV-202608-769 | 08/04/2026 | R1109 | Pantoprazole 40 mg TAB EC | 99999000601 | 28 | Facility | $58.24 | $17.92 |
| INV-202608-791 | 08/06/2026 | R1110 | Pantoprazole 40 mg TAB EC | 99999000601 | 26 | Facility | $54.08 | $16.64 |
| INV-202608-825 | 08/09/2026 | R1112 | Pantoprazole 40 mg TAB EC | 99999000601 | 23 | Facility | $47.84 | $14.72 |
| INV-202608-847 | 08/10/2026 | R1058 | Pantoprazole 40 mg TAB EC | 99999000601 | 22 | Facility | $45.76 | $14.08 |
| INV-202608-927 | 08/15/2026 | R1116 | Pantoprazole 40 mg TAB EC | 99999000601 | 17 | Facility | $35.36 | $10.88 |
| INV-202608-1050 | 08/22/2026 | R1038 | Pantoprazole 40 mg TAB EC | 99999000601 | 10 | Facility | $20.80 | $6.40 |
| INV-202608-1062 | 08/22/2026 | R1098 | Pantoprazole 40 mg TAB EC | 99999000601 | 10 | Facility | $20.80 | $6.40 |
| INV-202608-1087 | 08/22/2026 | R1120 | Pantoprazole 40 mg TAB EC | 99999000601 | 10 | Facility | $20.80 | $6.40 |
| INV-202608-1117 | 08/24/2026 | R1077 | Pantoprazole 40 mg TAB EC | 99999000601 | 8 | Facility | $16.64 | $5.12 |
| INV-202608-1130 | 08/24/2026 | R1121 | Pantoprazole 40 mg TAB EC | 99999000601 | 8 | Facility | $16.64 | $5.12 |
| INV-202608-1171 | 08/27/2026 | R1050 | Pantoprazole 40 mg TAB EC | 99999000601 | 35 | Facility | $72.80 | $22.40 |
2 line(s) of Eliquis 5 mg TAB (NDC 99999004001) billed at $8.82 per unit. Contract price: AWP $9.8000 less 16% (brand) = $8.2320 per unit. AWP is as printed on the pharmacy invoice.
Exhibit B §1 (Drug Pricing): brand AWP less 16%; generic AWP less 55%
Request credit for the difference and ask the pharmacy to correct its price file.
12/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202609-516 | 09/01/2026 | R1098 | Eliquis 5 mg TAB | 99999004001 | 60 | Facility | $529.20 | $35.28 |
| INV-202609-707 | 09/01/2026 | R1118 | Eliquis 5 mg TAB | 99999004001 | 60 | Facility | $529.20 | $35.28 |
Opportunities, not overbilling. Dollar figures are estimates based on an assumed 50% lower cost for the generic. Every item requires clinical pharmacist and prescriber review before any change.
25 facility-paid line(s) of brand Namenda, $15,065.57 total, across 14 resident(s). A generic (memantine) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote.
Formulary / therapeutic interchange terms (if any)
Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-572 | 07/01/2026 | R1086 | Namenda 10 mg TAB | 99999004401 | 62 | Facility | $828.07 | $414.04 |
| INV-202607-787 | 07/10/2026 | R1086 | Namenda 10 mg TAB | 99999004401 | 44 | Facility | $587.66 | $293.83 |
| INV-202607-943 | 07/24/2026 | R1102 | Namenda 10 mg TAB | 99999004401 | 16 | Facility | $213.70 | $106.85 |
| INV-202608-631 | 08/01/2026 | R1101 | Namenda 10 mg TAB | 99999004401 | 62 | Facility | $828.07 | $414.04 |
| INV-202608-651 | 08/01/2026 | R1102 | Namenda 10 mg TAB | 99999004401 | 62 | Facility | $828.07 | $414.04 |
| INV-202608-775 | 08/04/2026 | R1109 | Namenda 10 mg TAB | 99999004401 | 56 | Facility | $747.94 | $373.97 |
| INV-202608-874 | 08/12/2026 | R1113 | Namenda 10 mg TAB | 99999004401 | 40 | Facility | $534.24 | $267.12 |
| INV-202608-896 | 08/13/2026 | R1114 | Namenda 10 mg TAB | 99999004401 | 38 | Facility | $507.53 | $253.77 |
| INV-202608-956 | 08/16/2026 | R1117 | Namenda 10 mg TAB | 99999004401 | 32 | Facility | $427.39 | $213.70 |
| INV-202608-976 | 08/16/2026 | R1118 | Namenda 10 mg TAB | 99999004401 | 32 | Facility | $427.39 | $213.70 |
| INV-202608-1004 | 08/17/2026 | R1119 | Namenda 10 mg TAB | 99999004401 | 30 | Facility | $400.68 | $200.34 |
| INV-202608-1092 | 08/22/2026 | R1120 | Namenda 10 mg TAB | 99999004401 | 20 | Facility | $267.12 | $133.56 |
| INV-202609-592 | 09/01/2026 | R1109 | Namenda 10 mg TAB | 99999004401 | 60 | Facility | $801.36 | $400.68 |
| INV-202609-648 | 09/01/2026 | R1114 | Namenda 10 mg TAB | 99999004401 | 60 | Facility | $801.36 | $400.68 |
| INV-202609-689 | 09/01/2026 | R1117 | Namenda 10 mg TAB | 99999004401 | 60 | Facility | $801.36 | $400.68 |
| INV-202609-709 | 09/01/2026 | R1118 | Namenda 10 mg TAB | 99999004401 | 60 | Facility | $801.36 | $400.68 |
| INV-202609-729 | 09/01/2026 | R1119 | Namenda 10 mg TAB | 99999004401 | 60 | Facility | $801.36 | $400.68 |
| INV-202609-749 | 09/01/2026 | R1120 | Namenda 10 mg TAB | 99999004401 | 60 | Facility | $801.36 | $400.68 |
| INV-202609-946 | 09/12/2026 | R1129 | Namenda 10 mg TAB | 99999004401 | 38 | Facility | $507.53 | $253.77 |
| INV-202609-1056 | 09/19/2026 | R1132 | Namenda 10 mg TAB | 99999004401 | 24 | Facility | $320.54 | $160.27 |
20 facility-paid line(s) of brand Lipitor, $5,701.59 total, across 10 resident(s). A generic (atorvastatin) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote.
Formulary / therapeutic interchange terms (if any)
Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-401 | 07/01/2026 | R1068 | Lipitor 40 mg TAB | 99999004201 | 31 | Facility | $369.77 | $184.89 |
| INV-202607-630 | 07/01/2026 | R1089 | Lipitor 40 mg TAB | 99999004201 | 31 | Facility | $369.77 | $184.89 |
| INV-202607-809 | 07/11/2026 | R1098 | Lipitor 40 mg TAB | 99999004201 | 21 | Facility | $250.49 | $125.25 |
| INV-202607-961 | 07/25/2026 | R1089 | Lipitor 40 mg TAB | 99999004201 | 7 | Facility | $83.50 | $41.75 |
| INV-202608-375 | 08/01/2026 | R1068 | Lipitor 40 mg TAB | 99999004201 | 31 | Facility | $369.77 | $184.89 |
| INV-202608-588 | 08/01/2026 | R1098 | Lipitor 40 mg TAB | 99999004201 | 31 | Facility | $369.77 | $184.89 |
| INV-202608-693 | 08/01/2026 | R1107 | Lipitor 40 mg TAB | 99999004201 | 31 | Facility | $369.77 | $184.89 |
| INV-202608-1071 | 08/22/2026 | R1098 | Lipitor 40 mg TAB | 99999004201 | 10 | Facility | $119.28 | $59.64 |
| INV-202608-1108 | 08/23/2026 | R1045 | Lipitor 40 mg TAB | 99999004201 | 9 | Facility | $107.35 | $53.68 |
| INV-202608-1136 | 08/24/2026 | R1121 | Lipitor 40 mg TAB | 99999004201 | 8 | Facility | $95.42 | $47.71 |
| INV-202608-1157 | 08/24/2026 | R1122 | Lipitor 40 mg TAB | 99999004201 | 8 | Facility | $95.42 | $47.71 |
| INV-202609-230 | 09/01/2026 | R1045 | Lipitor 40 mg TAB | 99999004201 | 30 | Facility | $357.84 | $178.92 |
| INV-202609-365 | 09/01/2026 | R1068 | Lipitor 40 mg TAB | 99999004201 | 30 | Facility | $357.84 | $178.92 |
| INV-202609-517 | 09/01/2026 | R1098 | Lipitor 40 mg TAB | 99999004201 | 30 | Facility | $357.84 | $178.92 |
| INV-202609-557 | 09/01/2026 | R1107 | Lipitor 40 mg TAB | 99999004201 | 30 | Facility | $357.84 | $178.92 |
| INV-202609-769 | 09/01/2026 | R1122 | Lipitor 40 mg TAB | 99999004201 | 30 | Facility | $357.84 | $178.92 |
| INV-202609-816 | 09/02/2026 | R1123 | Lipitor 40 mg TAB | 99999004201 | 29 | Facility | $345.91 | $172.96 |
| INV-202609-945 | 09/12/2026 | R1129 | Lipitor 40 mg TAB | 99999004201 | 19 | Facility | $226.63 | $113.32 |
14 facility-paid line(s) of brand Seroquel, $5,440.53 total, across 9 resident(s). A generic (quetiapine) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote.
Formulary / therapeutic interchange terms (if any)
Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-362 | 07/01/2026 | R1063 | Seroquel 50 mg TAB | 99999004301 | 31 | Facility | $479.14 | $239.57 |
| INV-202607-835 | 07/13/2026 | R1099 | Seroquel 50 mg TAB | 99999004301 | 19 | Facility | $293.66 | $146.83 |
| INV-202608-336 | 08/01/2026 | R1063 | Seroquel 50 mg TAB | 99999004301 | 31 | Facility | $479.14 | $239.57 |
| INV-202608-711 | 08/01/2026 | R1108 | Seroquel 50 mg TAB | 99999004301 | 31 | Facility | $479.14 | $239.57 |
| INV-202608-975 | 08/16/2026 | R1118 | Seroquel 50 mg TAB | 99999004301 | 16 | Facility | $247.30 | $123.65 |
| INV-202608-1137 | 08/24/2026 | R1121 | Seroquel 50 mg TAB | 99999004301 | 8 | Facility | $123.65 | $61.83 |
| INV-202609-332 | 09/01/2026 | R1063 | Seroquel 50 mg TAB | 99999004301 | 30 | Facility | $463.68 | $231.84 |
| INV-202609-575 | 09/01/2026 | R1108 | Seroquel 50 mg TAB | 99999004301 | 30 | Facility | $463.68 | $231.84 |
| INV-202609-708 | 09/01/2026 | R1118 | Seroquel 50 mg TAB | 99999004301 | 30 | Facility | $463.68 | $231.84 |
| INV-202609-859 | 09/07/2026 | R1125 | Seroquel 50 mg TAB | 99999004301 | 24 | Facility | $370.94 | $185.47 |
| INV-202609-1117 | 09/22/2026 | R1134 | Seroquel 50 mg TAB | 99999004301 | 9 | Facility | $139.10 | $69.55 |
9 facility-paid line(s) of brand Synthroid, $562.63 total, across 5 resident(s). A generic (levothyroxine) is available. Estimated savings assume a 50% lower cost; this is an assumption, not a quote. Narrow therapeutic index: monitor TSH after switching.
Formulary / therapeutic interchange terms (if any)
Clinical pharmacist to review each resident with the prescriber. Check for dispense-as-written orders before any change.
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-981 | 07/25/2026 | R1103 | Synthroid 75 mcg TAB | 99999004501 | 7 | Facility | $19.99 | $10.00 |
| INV-202608-776 | 08/04/2026 | R1109 | Synthroid 75 mcg TAB | 99999004501 | 28 | Facility | $79.97 | $39.99 |
| INV-202608-814 | 08/09/2026 | R1111 | Synthroid 75 mcg TAB | 99999004501 | 23 | Facility | $65.69 | $32.85 |
| INV-202608-833 | 08/09/2026 | R1112 | Synthroid 75 mcg TAB | 99999004501 | 23 | Facility | $65.69 | $32.85 |
| INV-202609-593 | 09/01/2026 | R1109 | Synthroid 75 mcg TAB | 99999004501 | 30 | Facility | $85.68 | $42.84 |
| INV-202609-610 | 09/01/2026 | R1111 | Synthroid 75 mcg TAB | 99999004501 | 30 | Facility | $85.68 | $42.84 |
| INV-202609-629 | 09/01/2026 | R1112 | Synthroid 75 mcg TAB | 99999004501 | 30 | Facility | $85.68 | $42.84 |
| INV-202609-1077 | 09/19/2026 | R1133 | Synthroid 75 mcg TAB | 99999004501 | 12 | Facility | $34.27 | $17.14 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 09/03/2026 were billed to the facility after the resident's plan rejected the claim (reject code 76); reason on the invoice: Plan Limitations Exceeded. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.
Census: R1016 in house, payer Medicaid, from 03/30/2024. Last census event: admit on 03/30/2024 (payer Medicaid).
§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage
Resubmit with the correct quantity / days supply, or request a quantity-limit exception from the plan; credit the facility for the resubmitted amount.
12/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202609-842 | 09/03/2026 | R1016 | Jardiance 10 mg TAB | 99999004101 | 28 | Facility | $505.68 | $505.68 |
| INV-202609-843 | 09/03/2026 | R1016 | Dispensing Fee | 99999004101 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/05/2026 were billed to the facility after the resident's plan rejected the claim (reject code MR); reason on the invoice: Product Not On Formulary. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.
Census: R1013 in house, payer Medicaid, from 12/29/2024. Last census event: admit on 12/29/2024 (payer Medicaid).
§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage
Ask whether the plan's transition process applies (temporary supply), request a formulary exception, or ask the prescriber to switch to a formulary alternative; resubmit and credit the facility.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-787 | 08/05/2026 | R1013 | Linzess 145 mcg CAP | 99999004901 | 27 | Facility | $403.70 | $403.70 |
| INV-202608-788 | 08/05/2026 | R1013 | Dispensing Fee | 99999004901 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 09/09/2026 were billed to the facility after the resident's plan rejected the claim (reject code 65); reason on the invoice: M/I Eligibility - Patient Not Covered. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.
Census: R1018 in house, payer Medicaid, from 11/27/2025. Last census event: admit on 11/27/2025 (payer Medicaid).
§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage
Ask the pharmacy for the full reject message, correct the eligibility or claim data, resubmit to the plan, and credit the facility.
12/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202609-923 | 09/09/2026 | R1018 | Januvia 100 mg TAB | 99999004701 | 22 | Facility | $349.27 | $349.27 |
| INV-202609-924 | 09/09/2026 | R1018 | Dispensing Fee | 99999004701 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 07/14/2026 were billed to the facility after the resident's plan rejected the claim (reject code 75); reason on the invoice: Prior Authorization Required. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.
Census: R1012 in house, payer Medicaid, from 06/29/2024. Last census event: admit on 06/29/2024 (payer Medicaid).
§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage
Ask the prescriber and the pharmacy to request prior authorization (or a coverage determination) and a transition supply from the plan, resubmit the claim once approved, and credit the facility.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-873 | 07/14/2026 | R1012 | Eliquis 5 mg TAB | 99999004001 | 36 | Facility | $296.35 | $296.35 |
| INV-202607-874 | 07/14/2026 | R1012 | Dispensing Fee | 99999004001 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/18/2026 were billed to the facility after the resident's plan rejected the claim (reject code 79); reason on the invoice: Refill Too Soon. Census payer on those dates: Medicaid, a day the facility is not responsible for drugs under a Part A stay. The agreement lets the pharmacy bill the facility for rejected claims, so the charge may be contractually valid; the question is whether the rejection was avoidable. Context: 42 CFR 423.120(b)(3) requires Part D plans to run a transition process that gives a temporary supply of non-formulary drugs and of formulary drugs that need prior authorization or step therapy, with provisions for long-term care residents. Whether this claim qualified is not determined here. The amount is recoverable only if the rejection is resolved; it needs human review.
Census: R1015 in house, payer Medicaid, from 08/29/2024. Last census event: admit on 08/29/2024 (payer Medicaid).
§5.3 (Facility Guarantee): facility pays for medications a resident's plan has denied, after the pharmacy has made reasonable efforts to obtain coverage
Resubmit when the fill becomes payable, or request the plan's override for a dose change, LOA or lost/destroyed medication; ask the pharmacy why a facility-paid fill was dispensed early.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-1017 | 08/18/2026 | R1015 | Xarelto 20 mg TAB | 99999004601 | 14 | Facility | $229.32 | $229.32 |
| INV-202608-1018 | 08/18/2026 | R1015 | Dispensing Fee | 99999004601 | 1 | Facility | $2.50 | $2.50 |
12 drug line(s) (plus 12 linked dispensing fee(s)) dispensed 07/06/2026–09/01/2026 were billed to the facility while Medicaid eligibility was pending. The census shows Medicaid approved on 09/10/2026, effective retroactively from 07/06/2026, so these dates are now a third party's responsibility. No matching credit appears on the invoices reviewed.
Census: R1135 in house, payer MedicaidPending, 07/06/2026–09/09/2026. Last census event: admit on 07/06/2026 (payer MedicaidPending). Retroactive approval: Medicaid from 07/06/2026, approved 09/10/2026.
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Send the pharmacy the eligibility approval and ask it to rebill Medicaid (or the resident's Part D plan) for these dates and credit the facility. Retro claims have filing deadlines: ask now.
10/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202607-711 | 07/06/2026 | R1135 | Atorvastatin 40 mg TAB | 99999000201 | 26 | Facility | $24.57 | $24.57 |
| INV-202607-712 | 07/06/2026 | R1135 | Docusate 100 mg CAP | 99999001401 | 52 | Facility | $1.87 | $1.87 |
| INV-202607-713 | 07/06/2026 | R1135 | Escitalopram 10 mg TAB | 99999002301 | 26 | Facility | $17.55 | $17.55 |
| INV-202607-714 | 07/06/2026 | R1135 | Mirtazapine 15 mg TAB | 99999002401 | 26 | Facility | $12.87 | $12.87 |
| INV-202608-720 | 08/01/2026 | R1135 | Atorvastatin 40 mg TAB | 99999000201 | 31 | Facility | $29.30 | $29.30 |
| INV-202608-721 | 08/01/2026 | R1135 | Docusate 100 mg CAP | 99999001401 | 62 | Facility | $2.23 | $2.23 |
| INV-202608-722 | 08/01/2026 | R1135 | Escitalopram 10 mg TAB | 99999002301 | 31 | Facility | $20.93 | $20.93 |
| INV-202608-723 | 08/01/2026 | R1135 | Mirtazapine 15 mg TAB | 99999002401 | 31 | Facility | $15.35 | $15.35 |
| INV-202609-782 | 09/01/2026 | R1135 | Atorvastatin 40 mg TAB | 99999000201 | 30 | Facility | $28.35 | $28.35 |
| INV-202609-783 | 09/01/2026 | R1135 | Docusate 100 mg CAP | 99999001401 | 60 | Facility | $2.16 | $2.16 |
| INV-202609-784 | 09/01/2026 | R1135 | Escitalopram 10 mg TAB | 99999002301 | 30 | Facility | $20.25 | $20.25 |
| INV-202609-785 | 09/01/2026 | R1135 | Mirtazapine 15 mg TAB | 99999002401 | 30 | Facility | $14.85 | $14.85 |
| INV-202607-715 | 07/06/2026 | R1135 | Dispensing Fee | 99999000201 | 1 | Facility | $2.50 | $2.50 |
| INV-202607-716 | 07/06/2026 | R1135 | Dispensing Fee | 99999001401 | 1 | Facility | $2.50 | $2.50 |
| INV-202607-717 | 07/06/2026 | R1135 | Dispensing Fee | 99999002301 | 1 | Facility | $2.50 | $2.50 |
| INV-202607-718 | 07/06/2026 | R1135 | Dispensing Fee | 99999002401 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-724 | 08/01/2026 | R1135 | Dispensing Fee | 99999000201 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-725 | 08/01/2026 | R1135 | Dispensing Fee | 99999001401 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-726 | 08/01/2026 | R1135 | Dispensing Fee | 99999002301 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-727 | 08/01/2026 | R1135 | Dispensing Fee | 99999002401 | 1 | Facility | $2.50 | $2.50 |
| INV-202609-786 | 09/01/2026 | R1135 | Dispensing Fee | 99999000201 | 1 | Facility | $2.50 | $2.50 |
| INV-202609-787 | 09/01/2026 | R1135 | Dispensing Fee | 99999001401 | 1 | Facility | $2.50 | $2.50 |
| INV-202609-788 | 09/01/2026 | R1135 | Dispensing Fee | 99999002301 | 1 | Facility | $2.50 | $2.50 |
| INV-202609-789 | 09/01/2026 | R1135 | Dispensing Fee | 99999002401 | 1 | Facility | $2.50 | $2.50 |
2 drug line(s) (plus 2 linked dispensing fee(s)) dispensed 08/19/2026 were billed to the facility while the resident was under hospice care (hospice election 08/18/2026). Under 42 CFR 418.106, drugs related to the palliation and management of the terminal illness and related conditions, as identified in the hospice plan of care, must be provided by the hospice while the patient is under hospice care. The invoice carries no diagnosis, so relatedness is not confirmed. Drugs unrelated to the terminal prognosis are normally billed to Part D or Medicaid, not the facility, so the facility should not be the payer either way.
Census: R1019 in house, payer Medicaid, from 04/23/2026. Last census event: admit on 04/23/2026 (payer Medicaid). Hospice: hospice election 08/18/2026.
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Confirm relatedness with the hospice and the consultant pharmacist against the hospice plan of care. For related drugs, bill the hospice (see the draft request to the hospice) or ask the pharmacy to bill the hospice and credit the facility. For unrelated drugs, ask the pharmacy to rebill Part D / Medicaid.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-1019 | 08/19/2026 | R1019 | Morphine Sulfate 20 mg/mL ORAL SOLN | 99999006501 | 28 | Facility | $20.16 | $20.16 |
| INV-202608-1020 | 08/19/2026 | R1019 | Haloperidol 0.5 mg TAB | 99999006601 | 28 | Facility | $5.67 | $5.67 |
| INV-202608-1021 | 08/19/2026 | R1019 | Dispensing Fee | 99999006501 | 1 | Facility | $2.50 | $2.50 |
| INV-202608-1022 | 08/19/2026 | R1019 | Dispensing Fee | 99999006601 | 1 | Facility | $2.50 | $2.50 |
1 drug line(s) (plus 1 linked dispensing fee(s)) dispensed 08/10/2026 were billed to the facility while the resident was under hospice care (census payer Hospice). Under 42 CFR 418.106, drugs related to the palliation and management of the terminal illness and related conditions, as identified in the hospice plan of care, must be provided by the hospice while the patient is under hospice care. The invoice carries no diagnosis, so relatedness is not confirmed. Drugs unrelated to the terminal prognosis are normally billed to Part D or Medicaid, not the facility, so the facility should not be the payer either way.
Census: R1001 in house, payer Hospice, from 11/06/2024. Last census event: admit on 11/06/2024 (payer Hospice). Hospice: census payer Hospice.
§5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Confirm relatedness with the hospice and the consultant pharmacist against the hospice plan of care. For related drugs, bill the hospice (see the draft request to the hospice) or ask the pharmacy to bill the hospice and credit the facility. For unrelated drugs, ask the pharmacy to rebill Part D / Medicaid.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-844 | 08/10/2026 | R1001 | Morphine Sulfate 20 mg/mL ORAL SOLN | 99999006501 | 28 | Facility | $20.16 | $20.16 |
| INV-202608-845 | 08/10/2026 | R1001 | Dispensing Fee | 99999006501 | 1 | Facility | $2.50 | $2.50 |
2 facility-paid OTC / house-stock line(s) of Bisacodyl 5 mg TAB EC (OTC) dispensed 08/01/2026–09/01/2026 on days outside a facility-responsible stay, billed at $0.12 per unit. Contract ceiling: OTC price list (NDC 99999007001) = $0.0600 per unit. OTC drugs are generally not covered by Part D, so the facility is often the payer; the price still has to match the agreement.
Census: R1022 in house, payer Medicaid, from 03/14/2026. Last census event: admit on 03/14/2026 (payer Medicaid).
Exhibit B §3 (House Stock and OTC): OTC items at the Exhibit B-3 price list
Request credit for the difference and ask the pharmacy to correct its OTC price file.
11/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202608-129 | 08/01/2026 | R1022 | Bisacodyl 5 mg TAB EC (OTC) | 99999007001 | 30 | Facility | $3.60 | $1.80 |
| INV-202609-115 | 09/01/2026 | R1022 | Bisacodyl 5 mg TAB EC (OTC) | 99999007001 | 30 | Facility | $3.60 | $1.80 |
1 facility-paid OTC / house-stock line(s) of Calcium Carbonate 500 mg CHEW TAB (OTC) dispensed 09/01/2026 on days outside a facility-responsible stay, billed at $0.11 per unit. Contract ceiling: OTC price list (NDC 99999007201) = $0.0700 per unit. OTC drugs are generally not covered by Part D, so the facility is often the payer; the price still has to match the agreement.
Census: R1025 in house, payer Medicaid, from 08/08/2024. Last census event: admit on 08/08/2024 (payer Medicaid).
Exhibit B §3 (House Stock and OTC): OTC items at the Exhibit B-3 price list
Request credit for the difference and ask the pharmacy to correct its OTC price file.
12/29/2026
| Line | Service | Resident | Item | NDC | Qty | Billed to | Line total | Flagged |
|---|---|---|---|---|---|---|---|---|
| INV-202609-128 | 09/01/2026 | R1025 | Calcium Carbonate 500 mg CHEW TAB (OTC) | 99999007201 | 60 | Facility | $6.60 | $2.40 |
| File | Name | Rows read | Loaded | Rejected | Unmapped columns |
|---|---|---|---|---|---|
| invoices | invoices.csv | 3,433 | 3,433 | 0 | — |
| census | census.csv | 268 | 268 | 0 | — |
I reviewed the consolidated-billing, substitution and clinically dependent findings in this report.
I reviewed every finding against the source invoice lines, census and agreement.